BIOSENIC news, videos and press releases
For more news please use our advanced search feature.
BIOSENIC - More news...
BIOSENIC - More news...
- BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023
- BioSenic S.A. : Transparency notifications received from François Rieger
- BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles
- BioSenic S.A. : Information on the total number of voting rights and shares
- BioSenic files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis
- BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease
- BioSenic provides third quarter 2023 Business Update
- BioSenic to draw the final tranches of its present Global Tech Opportunities 15 convertible bonds program and secure runway end of January 2024
- Correction: BioSenic S.A. : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS
- BioSenic S.A. : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS
- BioSenic S.A. : Information on the total number of voting rights and shares
- BioSenic receives a Chinese patent with broad claims, protecting the combined use of metal ions and arsenic salts to treat a wide range of serious diseases
- BioSenic S.A. : Information on the total number of voting rights and shares
- BioSenic provides further update on negotiations with its main creditors
- BioSenic SA : Information on the total number of voting rights and shares
- BioSenic reacquires global IP rights and provides update on JTA-004 development
- BioSenic identifies key biomarkers for cGvHD and submits patent to EPO
- BioSenic announces 2022 full year results
- BioSenic receives key European patent from EPO, for further therapeutic development in cancer, infectious and immune diseases
- BioSenic appoints Lieven Huysse, MD, as Chief Medical Officer
- BioSenic provides Financial Update and Financial Calendar 2023
- BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)
- BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population
- BioSenic SA: Information on the total number of voting rights and shares
- BioSenic announces initiation of coverage by Portzamparc and Gilbert Dupont
- BioSenic appoints Dr Carole Nicco as Chief Scientific Officer
- BioSenic SA : Information on the total number of voting rights and shares
- BioSenic appoints Michel Wurm, M.D. as Chief Medical Officer
- BioSenic SA provides update on its autoimmune disease platform based on ATO (arsenic trioxide)
- Bone Therapeutics SA: Transparency notification received from S.F.P.I/F.P.I.M
